-
EP4232031
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4232031
| EP4232031 - TREATMENTS OF ANGIOEDEMA [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 08.08.2025 Database last updated on 09.04.2026 | |
| Former | Request for examination was made Status updated on 28.07.2023 | ||
| Former | The international publication has been made Status updated on 30.04.2022 | ||
| Former | unknown Status updated on 24.11.2021 | Most recent event Tooltip | 27.02.2026 | New entry: Application deemed to be withdrawn: despatch of communication + time limit | Applicant(s) | For all designated states Kalvista Pharmaceuticals Limited Porton Science Park Bybrook Road Porton Down, Salisbury SP4 0BF Wiltshire / GB | [2023/35] | Inventor(s) | 01 /
COOPER, John Alexander Salisbury Wiltshire SP4 0BF / GB | 02 /
FEENER, Edward Paul Reading Massachusetts 01864 / US | 03 /
MAETZEL, Andreas Chapel Hill North Carolina 27516 / US | 04 /
MARSH, Sally Louise Salisbury Wiltshire SP4 0BF / GB | 05 /
SMITH, Michael David Salt Lake City Utah 84109 / US | 06 /
YEA, Christopher Martyn Salisbury Wiltshire SP4 0BF / GB | [2023/35] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2023/35] | Application number, filing date | 21806014.3 | 22.10.2021 | [2023/35] | WO2021GB52746 | Priority number, date | US202063104919P | 23.10.2020 Original published format: US 202063104919 P | US202163147595P | 09.02.2021 Original published format: US 202163147595 P | US202163212224P | 18.06.2021 Original published format: US 202163212224 P | US202163220747P | 12.07.2021 Original published format: US 202163220747 P | [2023/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022084693 | Date: | 28.04.2022 | Language: | EN | [2022/17] | Type: | A1 Application with search report | No.: | EP4232031 | Date: | 30.08.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.04.2022 takes the place of the publication of the European patent application. | [2023/35] | Search report(s) | International search report - published on: | EP | 28.04.2022 | Classification | IPC: | A61K31/4439, A61K31/444, A61P7/00 | [2023/35] | CPC: |
A61K31/444 (EP);
A61K31/4439 (EP,US);
A61K9/2018 (US);
A61P7/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/35] | Extension states | BA | 18.05.2023 | ME | 18.05.2023 | Validation states | KH | 18.05.2023 | MA | 18.05.2023 | MD | 18.05.2023 | TN | 18.05.2023 | Title | German: | BEHANDLUNGEN VON ANGIOÖDEMEN | [2023/35] | English: | TREATMENTS OF ANGIOEDEMA | [2023/35] | French: | TRAITEMENTS DE L'OEDÈME DE QUINCKE | [2023/35] | Entry into regional phase | 18.05.2023 | National basic fee paid | 18.05.2023 | Designation fee(s) paid | 18.05.2023 | Examination fee paid | Examination procedure | 18.05.2023 | Amendment by applicant (claims and/or description) | 18.05.2023 | Examination requested [2023/35] | 18.05.2023 | Date on which the examining division has become responsible | 11.08.2025 | Despatch of a communication from the examining division (Time limit: M06) | 26.02.2026 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | Fees paid | Renewal fee | 18.05.2023 | Renewal fee patent year 03 | 12.09.2024 | Renewal fee patent year 04 | 12.09.2025 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [ID] WO2019106361 (KALVISTA PHARMACEUTICALS LTD et al.) | [I] WO2017208005 (KALVISTA PHARMACEUTICALS LTD et al.) | [XP] WO2020249977 (KALVISTA PHARMACEUTICALS LTD et al.) | by applicant | WO03076458 | WO9204371 | WO9507921 | WO9429335 | WO2005123680 | US5187157 | WO2008049595 | WO2008016883 | WO2011118672 | WO2012004678 | WO2010142801 | WO2012017020 | WO2013005045 | WO2014108679 | WO2014188211 | WO2016083820 | GB2015053615 | WO2019106361 | WO2012009009 | K. D. BHOOLA ET AL.: "Encyclopedia of Respiratory Medicine", article "Kallikrein-Kinin Cascade", pages: 483 - 493 | J. W. BRYANT: "Human plasma kallikrein-kinin system: physiological and biochemical parameters", CARDIOVASCULAR AND HAEMATOLOGICAL AGENTS IN MEDICINAL CHEMISTRY, vol. 7, 2009, pages 234 - 250, XP055783779, DOI: 10.2174/187152509789105444 DOI: http://dx.doi.org/10.2174/187152509789105444 | K. D. BHOOLA ET AL., PHARMACOLOGICAL REV.,, vol. 44, 1992, pages 1 | D. J. CAMPBELL: "Towards understanding the kallikrein-kinin system: insights from the measurement of kinin peptides", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 33, 2000, pages 665 - 677 | HOFMAN ET AL., CLIN REV ALLERGY IMMUNOL, 2016 | MAAS ET AL., J CLINICAL INVEST, 2008 | F. MARCEAUD. REGOLI, NATURE REV., DRUG DISCOVERY, vol. 3, 2004, pages 845 - 852 | A. CLERMONT: "Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats", DIABETES, vol. 60, 2011, pages 1590 - 98 | VERONEZ ET AL., FRONT MED (LAUSANNE, vol. 6, 21 February 2019 (2019-02-21), pages 28 | RECKE ET AL., CLIN TRANSL ALLERGY., vol. 9, 14 February 2019 (2019-02-14), pages 9 | MANSI ET AL., THE ASSOCIATION FOR THE PUBLICATION OF THE JOURNAL OF INTERNAL MEDICINE JOURNAL OF INTERNAL MEDICINE, vol. 277, 2015, pages 585 - 593 | MAAT ET AL., J THROMB HAEMOST, vol. 17, no. l, January 2019 (2019-01-01), pages 183 - 194 | MAGERL ET AL., CLINICAL AND EXPERIMENTAL DERMATOLOGY, vol. 39, 2014, pages 298 - 303 | KEDARISETTY ET AL., OTOLARYNGOL HEAD NECK SURG., 30 April 2019 (2019-04-30), pages 194599819846446 | LONG, NANOTOXICOLOGY, vol. 10, no. 4, 2016, pages 501 - 11 | BAS ET AL., N ENGL J MED, 2015 | LEIBFRIEDKOVARY, J PHARM PRACT, 2017 | VAN DEN ELZEN ET AL., CLINIC REV ALLERG IMMUNOL, 2018 | HAN ET AL., JCI, 2002 | SIMAO ET AL., BLOOD, vol. 129, no. 16, 20 April 2017 (2017-04-20), pages 2280 - 2290 | FROHLICH ET AL., STROKE, 11 June 2019 (2019-06-11) | RATHBUN, OXF MED CASE REPORTS, 24 January 2019 (2019-01-24) | LEKOUBOU ET AL., NEUROL RES., vol. 36, no. 7, July 2014 (2014-07-01), pages 687 - 94 | HILL ET AL., NEUROLOGY, vol. 60, no. 9, 13 May 2003 (2003-05-13), pages 1525 - 7 | STONE ET AL., IMMUNOL ALLERGY CLIN NORTH AM., vol. 37, no. 3, August 2017 (2017-08-01), pages 483 - 495 | SCOTT, CURR DIABETES REV, vol. 14, no. 4, 2018, pages 327 - 333 | HERMANRUD ET AL., BMJ CASE REP., 10 January 2017 (2017-01-10) | KIM ET AL., BASIC CLIN PHARMACOL TOXICOL., vol. 124, no. 1, January 2019 (2019-01-01), pages 115 - 122 | REICHMAN ET AL., PHARMACOEPIDEMIOL DRUGSAF., vol. 26, no. 10, October 2017 (2017-10-01), pages 1190 - 1196 | DIESTRO ET AL., J STROKE CEREBROVASC DIS., vol. 28, no. 5, May 2019 (2019-05-01), pages e44 - e45 | GIARD ET AL., DERMATOLOGY, vol. 225, no. 1, 2012, pages 62 - 9 | HWANG ET AL., IMMUNOTHERAPY, vol. 11, no. 17, 2019, pages 1439 - 1444 | GARRETT ET AL.: "Peptide aldehyde...", J. PEPTIDE RES., vol. 52, 1998, pages 62 - 71 | T. GRIESBACHER ET AL.: "Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats", BRITISH JOURNAL OF PHARMACOLOGY, vol. 137, 2002, pages 692 - 700, XP002252617, DOI: 10.1038/sj.bjp.0704910 DOI: http://dx.doi.org/10.1038/sj.bjp.0704910 | D. M. EVANS ET AL., IMMUNOLPHARMACOLOGY, vol. 32, 1996, pages 115 - 116 | J. STURZBECHER ET AL., BRAZILIAN J. MED. BIOL. RES, vol. 27, 1994, pages 1929 - 34 | N. TENO ET AL., CHEM. PHARM. BULL., vol. 41, 1993, pages 1079 - 1090 | W. B. YOUNG ET AL.: "Small molecule inhibitors of plasma kallikrein", BIOORG. MED. CHEM. LETTS., vol. 16, 2006, pages 2034 - 2036, XP025107021, DOI: 10.1016/j.bmcl.2005.12.060 DOI: http://dx.doi.org/10.1016/j.bmcl.2005.12.060 | OKADA ET AL.: "Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship", CHEM. PHARM. BULL., vol. 48, 2000, pages 1964 - 72, XP002189579 | ZHANG ET AL.: "Discovery of highly potent small molecule kallikrein inhibitors", MEDICINAL CHEMISTRY, vol. 2, 2006, pages 545 - 553 | KOLTE ET AL.: "Biochemical characterization of a novel high-affinity and specific kallikrein inhibitor", BRITISH JOURNAL OF PHARMACOLOGY, vol. 162, no. 7, 2011, pages 1639 - 1649, XP055783781, DOI: 10.1111/j.1476-5381.2010.01170.x DOI: http://dx.doi.org/10.1111/j.1476-5381.2010.01170.x | A. LEHMANN: "Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery", EXPERT OPIN. BIOL. THER., vol. 8, pages 1187 - 99, XP008153852, DOI: 10.1517/14712598.8.8.1187 DOI: http://dx.doi.org/10.1517/14712598.8.8.1187 | TAMIE J. CHILCOTESUKANTO SINHA: "ASP-634: An Oral Drug Candidate for Diabetic MacularEdema", ARVO, 6 May 2012 (2012-05-06) | MAURER M ET AL., PLOS ONE, vol. 8, no. 2, 2013, pages e53773 | STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection and Use", 2002, WILEY-VCH | ALLERGY ASTHMA PROC., vol. 39, no. 1, 1 January 2018 (2018-01-01), pages 74 - 80 | CAS , no. 318496-66-1 | JOHANSEN ET AL., INT. J. TISS. REAC., vol. 8, 1986, pages 185 | SHORI ET AL., BIOCHEM. PHARMACOL., vol. 43, 1992, pages 1209 | STURZEBECHER ET AL., BIOL. CHEM. HOPPE-SEYLER, vol. 373, 1992, pages 1025 | FEINGOLDGILLESPIE: "Crossover trials with censored data", STATISTICS IN MEDICINE, vol. 15, no. 10, 1996, pages 953 - 967 | "The comparison of success rates in cross-over trials in the presence of an order effect", APPLIED STATISTICS, vol. 30, 1981, pages 9 - 15 | LUMRY ET AL., ANN ALLERGY ASTHMA IMMUNOL., vol. 107, 2011, pages 529 - 537 |